Taking aim at Astellas and Medivation, J&J moves prostate cancer drug into late-stage testing
This article was originally published in Scrip
Executive Summary
Johnson & Johnson moved a recently acquired prostate cancer drug into late-stage testing as it tries to keep its market lead over rivals Astellas Pharma and Medivation.